INCR (Intercure) Tariff Resilience Score: 5/10 (As of Sep. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

INCR Intercure Ltd INCR
67 GF Score
Price $5.42
GF Value $6.18
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Intercure Tariff Resilience Score?

Intercure INCR +1.59% 67 Tariff Resilience Score is 5 as of Sep. 04, 2026. GuruFocus rates INCR with a GF Score™ of 67/100 and a GF Value™ of $6.18 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,024 Drug Manufacturers companies, Intercure ranks better than 84.37% on this metric.

Intercure has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Intercure has Intercure, operating in the cannabis sector, faces moderate tariff risks due to international supply chain dependencies. While it has some pricing power, historical impacts from tariffs have been mixed. It can explore alternative suppliers to mitigate risks.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Intercure might have Average Resilient.

Intercure  (NAS:INCR) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Intercure Tariff Resilience Score Related Terms

INCR vs CTOR, ZYBT, TLPH: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Intercure's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Intercure Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intercure's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Intercure's Tariff Resilience Score falls into.


INCR
67GF Score
Intercure Ltd INCR
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Intercure (INCR) has a Tariff Resilience Score of 5 as of Sep. 04, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Intercure ranks #160 out of 1024 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Intercure's Tariff Resilience Score too high?
Intercure's current Tariff Resilience Score is 5. Based on the distribution chart, Intercure ranks #160 out of 1024 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Intercure has a GF Score™ of 67/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Intercure's Tariff Resilience Score compare to CTOR and ZYBT?
According to the Drug Manufacturers industry distribution chart, Intercure ranks #160 out of 1024 companies for Tariff Resilience Score. This places Intercure in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Intercure's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intercure stock overvalued right now?
Based on GuruFocus' analysis, Intercure (INCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $6.18, compared to a current price of $5.42 — trading 12.3% below its estimated fair value. The current Tariff Resilience Score is 5. Intercure's overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Intercure (INCR), the current Tariff Resilience Score is 5 as of Sep. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intercure (INCR) Overvalued in 2026?

Based on GuruFocus' analysis, Intercure stock appears to be undervalued. The current stock price of $5.42 is trading 12.3% below its estimated GF Value™ of $6.18. GuruFocus considers Intercure to be Modestly Undervalued.

Key valuation signals for INCR:

  • Tariff Resilience Score: 5
  • GF Value™: $6.18 vs. price of $5.42 (12.3% below fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the INCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intercure Business Description

Other Exchanges INCR:Israel
Address 85 Medinat ha-Yehudim Street, Herzliya, ISR, 4676670
Intercure Ltd is engaged in the research, cultivation, production, and distribution of pharma-grade cannabis-based products. Its products are available in dried inflorescences or liquid oil form, and are marketed through various brands, including Pharmo Cann, Humboldt, Indoor, Space Labs, Canndoc Utopia, Binske, Canndoc Stars, and others. The company has two operating segments, namely Investments in portfolio companies in the biomed sector and Investments in the medical cannabis sector. A majority of its revenue is generated from the Cannabis segment.
67GF Score

Get the complete analysis for INCR

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.42
Price
$6.18
GF Value